Let's break down the importance of its Amazon deal and analyze what the business is still struggling with to ... But an even ...

On that note, Terns Pharmaceuticals ( TERN -5.84%) is a biotech developing weight loss therapies that's worth investing ...

CRISPR Therapeutics' first therapy is called Casgevy. It treats sickle cell disease (SCD) and beta thalassemia, both rare inherited illnesses that affect the function of a person's red blood cells. It ...

ATI Physical Therapy, Inc. (ATIP) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings ...

Despite lagging behind on clinical trial timelines, Atai Life Sciences still has a deep development portfolio. Read here for ...

Inogen primarily develops, manufactures and markets innovative POCs to deliver supplemental long-term oxygen therapy (LTOT) ...

Iovance Biotherapeutics (NASDAQ: IOVA) investors received great news earlier this year when the U.S. Food and Drug Administration granted it accelerated approval for the company's cell therapy ...

With transformation efforts, M&As and revenue diversification expected to boost the healthcare market, should investors ...

“I’m very upfront,” she said. “I say: ‘This is my business. This is my livelihood.’” One reason for therapy sticker shock is that most people are used to annual or infrequent visits ...

Bicara Therapeutics, a TPG-backed biopharmaceutical company developing a therapy targeting tumors, said on Wednesday it plans ...

Emily Bodnar, an analyst from H.C. Wainwright, maintained the Buy rating on IO Biotech (IOBT – Research Report). The associated price ...

Inc. (Nasdaq: BLUE) today announced that it has completed the restatement of its consolidated financial statements for the ...